Nectar Lifesciences Limited has informed the Exchange regarding 'Satisfaction of charge on full repayment of secured debt, along with the accrued interest to consortium lenders'.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nectar Lifesciences has fully repaid its secured debt along with accrued interest to its consortium lenders. As a result of this full repayment, the charge created on the company's assets in favour of the lenders stands satisfied and discharged. The company has informed the stock exchange about this development. No new credit facility or fresh borrowing has been mentioned in this filing.
This is a positive development for shareholders, as it signals debt reduction and improved financial flexibility for the company. Lower debt burden can lead to reduced interest costs, better creditworthiness, and potentially improved investor confidence in the stock.